China’s Anti-Monopoly Efforts To Focus On Six Sectors Including Pharma
This article was originally published in PharmAsia News
China’s National Development and Reform Commission’s anti-price monopoly efforts will focus on six industries including pharma, according to an NDRC price regulation and anti-monopoly official.
You may also be interested in...
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.